Strain Improvement Program of Streptomyces roseosporus for Daptomycin Production.
Bioassay
Daptomycin
Fermentation
Lipopeptide antibiotic
Mutagenesis
Rational screening
Streptomyces filamentosus
Streptomyces roseosporus
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
12
5
2021
pubmed:
13
5
2021
medline:
23
6
2021
Statut:
ppublish
Résumé
Daptomycin is a cyclic lipopeptide antibiotic with potent activity against gram-positive bacteria. It has a calcium-dependent mechanism of action that disrupts multiple features of the bacterial membrane function. This antibiotic is highly demanded due to its effectiveness against to microorganisms resistant to other antibiotics, including vancomycin-resistant Staphylococcus aureus (VRSA) and methicillin-resistant S. aureus (MRSA). Daptomycin is produced by fermentation of Streptomyces roseosporus, currently identified as Streptomyces filamentosus. However, low fermentation yields and high production costs are reported. This chapter describes a method of strain improvement involving random mutagenesis, rational screening by bioassay, and flask fermentation. The ultimate objective is to select mutants of S. roseosporus overproducing daptomycin in order to design a more cost-effective daptomycin production.
Identifiants
pubmed: 33977458
doi: 10.1007/978-1-0716-1358-0_20
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Daptomycin
NWQ5N31VKK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-363Références
Boeck LD, Fukuda DS, Abbott BJ, Debono M (1988) Deacylation of A21978C, an acidic lipopeptide antibiotic complex, by Actinoplanes utahensis. J Antibiot (Tokyo) 41(8): 1085–1092
doi: 10.7164/antibiotics.41.1085
Akins RL, Rybak MJ (2001) Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamics model with simulated endocardial vegetations. Antimicrob Agents Chemother 45:454–459
doi: 10.1128/AAC.45.2.454-459.2001
Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355(7):653–665
doi: 10.1056/NEJMoa053783
Debono M, Abbott BJ, Molloy RM, Fukuda DS, Hunt AH, Daupert VM, Counter FT, Ott JL, Carrell CB, Howard LC (1988) Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot 41(8):1093–1105
doi: 10.7164/antibiotics.41.1093
King A, Phillips I (2001) The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 48(2):219–223
doi: 10.1093/jac/48.2.219
Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948–2953
doi: 10.1128/AAC.44.11.2948-2953.2000
Taylor SD, Palmer M (2016) The action mechanism of daptomycin. Bioorg Med Chem 24(24):6253–6268
doi: 10.1016/j.bmc.2016.05.052
Debono M, Barnhart M, Carrell CB, Hoffmann JA, Occolowitz JL, Abbott BJ, Fukuda DS, Hamill RL, Biemann K, Herlihy WC (1987) A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J Antibiot 40(6):761–777
doi: 10.7164/antibiotics.40.761
Abbott BJ, Debono M, Fukuda DS (1985) Derivatives of a A-21978C cyclic peptides. US patent 4.537.717
Huber FM, Pieper RL, Tietz AJ, Eaton TE, Ford LM, Godfrey OW Jr, Huber MLB, Zmijewski MJ Jr (1991) Production of A-21978C derivatives. European Patent No. EP0178152B1
Lu W, Fan J, Wen J, Xia Z, Caiyin Q (2011) Kinetic analysis and modeling of daptomycin batch fermentation by Streptomyces roseosporus. Appl Biochem Biotechnol 163(4):453–462
doi: 10.1007/s12010-010-9053-6
Wang L, Zhao Y, Liu Q, Huan Y, Hu C, Liao G (2012) Improvement of A21978C production in Streptomyces roseosporus by reporter-guided rpsL mutation selection. J Appl Microbiol 112(6):1095–1101
doi: 10.1111/j.1365-2672.2012.05302.x
Yu G, Jia X, Wen J, Lu W, Wang G, Caiyin Q, Chen Y (2011) Strain improvement of Streptomyces roseosporus for daptomycin production by rational screening of He-Ne laser and NTG induced mutants and kinetic modeling. Appl Biochem Biotechnol 163(6):729–743
doi: 10.1007/s12010-010-9078-x
Huber FM, Pieper RL, Tiezt AJ (1988) The formation of daptomycin by supplying decanoic acid to Streptomyces roseosporus cultures producing the antibiotic complex A21978C. J Biotechnol 7 (4):283–292
doi: 10.1016/0168-1656(88)90040-5
Tian X, Zhang Z, Yang T, Chen M, Li J, Chen F, Yang J, Li W, Zhang B, Zhang Z, Wu J, Zhang C, Long L, Xiao J (2016) Comparative genomics analysis of Streptomyces species reveals their adaptation to the marine environment and their diversity at the genomic level. Front Microbiol 7:998
pubmed: 27446038
pmcid: 4921485
Lee SK, Kim HR, Jin YY, Yang SH, Suh JW (2016) Improvement of daptomycin production via increased resistance to decanoic acid in Streptomyces roseosporus. J Biosci Bioeng 122:427–433
doi: 10.1016/j.jbiosc.2016.03.026
Chauvenet W (1863) A manual of spherical and practical astronomy. J. B. Lippincott & Company, Philadelphia, PA